Latest Zero Pharmaceuticals Inc. Stories

IRVINE, Calif., Nov. 14, 2012 /PRNewswire/ -- GZP is announcing expansion of its longstanding capabilities in helping its clients develop biosimilars and drug or biologic/diagnostic device personalized medicine programs for FDA and EMA review. New legislative initiatives in the US and subsequent regulations and guidelines have provided a number of pathways for development of biosimilars, with the associated requirements for intensive planning and execution of nonclinical and clinical...